IRLAB receives approval to initiate Phase II trial with IRL752

August 25, 2017

IRLAB has received approval from Läkemedelsverket (the Swedish MPA) and Regionala Etikprövningsnämnden, EPN, (the Ethics committee, Stockholm) to conduct a Phase II clinical trial with IRL752. IRL752 is a cortical enhancer designed to treat Parkinsons disease dementia.

“The approval from the MPA and the ethics committee is very encouraging. The Phase II study with IRL752 is a double-blind placebo controlled study in patients with Parkinson’s disease and dementia. About 80 % of all patients suffering from Parkinson’s disease  develops symptoms of dementia which, today, lack satisfactory treatment.”. says Joakim Tedroff, IRLAB’s chief medical officer (CMO)

For full press release, click here for English version and here for Swedish version.